Tag Archives: NASDAQ:HQY

Healthequity (HQY) Received its Third Buy in a Row

After KeyBanc and Citigroup gave Healthequity (NASDAQ: HQY) a Buy rating last month, the company received another Buy, this time from Cantor Fitzgerald. Analyst Steven Halper reiterated a Buy rating on Healthequity today and set a price target of $80.

Why Did Cantor Fitzgerald Upgrade Healthequity’s Stock?

In a report released today, Steven Halper from Cantor Fitzgerald upgraded Healthequity (HQY – Research Report) to Buy, with a price target of $82. The company’s shares opened today at $59.63. Halper noted: “. We are upgrading the shares of

Healthequity (HQY) Gets a Hold Rating from Cantor Fitzgerald

Cantor Fitzgerald analyst Steven Halper reiterated a Hold rating on Healthequity (HQY – Research Report) today and set a price target of $82. The company’s shares closed on Tuesday at $83.60. Halper said: “. We reiterate our Neutral rating on

Raymond James Believes Healthequity (NASDAQ: HQY) Still Has Room to Grow

In a report released today, Charles Peters from Raymond James maintained a Buy rating on Healthequity (NASDAQ: HQY), with a price target of $105. The company’s shares closed on Friday at $97.07, close to its 52-week high of $97.94. According

Barrington Believes Healthequity (NASDAQ: HQY) Won’t Stop Here

Barrington analyst Alexander Paris reiterated a Buy rating on Healthequity (NASDAQ: HQY) today and set a price target of $100. The company’s shares opened today at $92.89, close to its 52-week high of $97.94. Paris observed: “We are maintaining our

Healthequity (HQY) Gets a Buy Rating from Oppenheimer

Oppenheimer analyst Mohan Naidu maintained a Buy rating on Healthequity (NASDAQ: HQY) today and set a price target of $104. The company’s shares closed yesterday at $94.47, close to its 52-week high of $96.29. Naidu wrote: “HealthEquity Q2 beat our